Actinogen 招募第 100 名患者参加针对脑皮质醇的阿尔茨海默病新药 Xanamem 的高级试验。 Actinogen enrolls 100th patient in advanced trial for new Alzheimer's drug Xanamem, targeting brain cortisol.

Actinogen Medical 已招募第 100 名参与者参加 Xanamem 的 2b/3 期试验，Xanamem 是一种针对大脑皮质醇水平的新型阿尔茨海默病治疗方法。 Actinogen Medical has enrolled its 100th participant in a phase 2b/3 trial for Xanamem, a new Alzheimer's treatment targeting cortisol levels in the brain. 临时分析定于2026年1月进行,预计到2026年底取得最后结果。 An interim analysis is scheduled for January 2026, with final results expected by late 2026. 该公司计划在今年晚些时候与FDA会面, 讨论监管部门的批准途径. The company plans to meet with the FDA later this year to discuss regulatory approval pathways. Xanamem可单独使用,也可与阿尔茨海默氏病的其他治疗方法一起使用。 Xanamem could be used alone or alongside other treatments for Alzheimer's.